Korean J Pediatr Gastroenterol Nutr.  2003 Sep;6(2):152-160.

The Comparison of Interferon-alpha Treatment by Dosages and Retreatment for Chronic Hepatitis B in Children

Affiliations
  • 1Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Korea. bhchoi@knu.ac.kr

Abstract

PURPOSE: We compared the therapeutic efficacy of low dose with that of standard dose of interferon (IFN) treatment and also compared the first IFN treatment with retreatment.
METHODS
We have studied 51 children (age, 2~14) treated for chronic hepatitis B from March 1990 to August 1999. Twenty seven children had been treated with 3 MU/m2 (2.66+/-0.66 MU/m2) of IFN-alpha three times a week for 6 months (range, 6~12 months), whereas 24 children with 6 MU/m2 (4.45+/-0.94 MU/m2). There was no significant difference in gender, age, initial ALT and HBV DNA levels between each comparative group.
RESULTS
Among the 27 children treated with 3 MU/m2 of IFN, ALT level had normalized in 11 children (41%) and anti-HBe seroconversion occurred in 9 children (33%) one year after the initiation of treatment. In comparison, among the 24 children treated with 6 MU/m2 of IFN, ALT normalized in 12 children (50%) and anti-HBe seroconversion occurred in 7 children (29%). In comparing the first treatment group to retreatment group, ALT level had normalized in 23 children (45%) and anti-HBe seroconversion occurred in 16 children (31%) among the 51 children treated with the first course of IFN treatment. In comparison, ALT normalized and anti-HBe seroconversion occurred in 3 children (25%) among the retreated 12 children.
CONCLUSION
There was no significant difference in the therapeutic efficacies between 3 MU/m2 and 6 MU/m2 dose of IFN treated groups in ALT normalization and anti-HBe seroconversion. The retreatment efficacy of IFN-alpha was as effective as the first treatment.

Keyword

Chronic Hepatitis B; Interferon; Treatment; Children

MeSH Terms

Child*
DNA
Hepatitis B, Chronic*
Hepatitis, Chronic*
Humans
Interferon-alpha*
Interferons
Retreatment*
DNA
Interferon-alpha
Interferons
Full Text Links
  • KJPGN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr